BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Neumedicines Inc. 

2708 Foothill Boulevard
Suite 403
La Crescenta  California  91214  U.S.A.
Phone: 818-606-2638 Fax: 818-293-0267


SEARCH JOBS


Industry
Biotechnology






 Company News
Neumedicines Inc. To Feature HemaMax Study Results In Presentation At Biotech Showcase Conference 1/9/2014 9:58:37 AM    More...
Neumedicines Inc.’ Study Shows HemaMax, Not Neupogen (G-CSF), Improves Survival Outcomes Following Lethal Irradiation 1/8/2014 9:06:43 AM    More...
Neumedicines Inc. Joins The Alliance For Biosecurity 1/2/2014 9:00:39 AM    More...
Neumedicines Inc. Presents HemaMax™ Clinical Data At The American Society of Hematology Conference 12/16/2013 9:26:40 AM    More...
Neumedicines Inc. Presents HemaMax™ Clinical Data At The American Society of Hematology Conference 12/13/2013 7:15:53 AM    More...
Neumedicines Inc. Receives an Award of $8.3 Million From Biomedical Advanced Research and Development Authority (BARDA) for Continued Development of HemaMax as a Countermeasure to Acute Radiation Exposure 6/10/2013 10:03:12 AM    More...
Neumedicines Inc. Receives Biomedical Advanced Research and Development Authority (BARDA) Notification of Intent to Exercise Contract Option to Continue Development of HemaMax as Radiation Medical Countermeasure 5/14/2013 10:06:31 AM    More...
Neumedicines Inc. Wins U.S. Federal Government Contract for up to $273 Million to Fund Late-Stage Development of HemaMax(TM), a Novel Radiation Medical Countermeasure 9/26/2011 10:28:21 AM    More...
Neumedicines Inc. Receives Notice of Allowance for Patent Covering Use of HemaMax(TM) (rIL-12) to Treat Chemotherapy-Induced Thrombocytopenia (CIT) 1/31/2011 9:40:49 AM    More...
Neumedicines Inc. Awarded BAA-BARDA-08-08 Contract by the Biomedical Advanced Research and Development Authority (BARDA) 9/19/2008 9:36:00 AM    More...

//-->